Biogen has scaled back its ambitions for Denali ... and decided not to go ahead with a phase2b trial of BIIB131 for ischaemic stroke.
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow morning. Here’s what to look for. Biogen beat analysts’ revenue expectations by 1.2% last quarter, reporting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback